These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 20136784

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?].
    Büchler M.
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S390-4. PubMed ID: 20129451
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM.
    Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
    [Abstract] [Full Text] [Related]

  • 5. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J.
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
    Dekter HE, Romijn FP, Temmink WP, van Pelt J, de Fijter JW, Smit NP.
    Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug insight: maintenance immunosuppression in kidney transplant recipients.
    Samaniego M, Becker BN, Djamali A.
    Nat Clin Pract Nephrol; 2006 Dec; 2(12):688-99. PubMed ID: 17124526
    [Abstract] [Full Text] [Related]

  • 14. De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
    Flechner S, Friend P, Campistol J, Weir M, Diekmann F, Russ G.
    Transplant Proc; 2009 Dec; 41(6 Suppl):S42-4. PubMed ID: 19651296
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G, Srinivas TR, Meier-Kriesche HU.
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
    Glowacki F, Dharancy S, Noël C, Hazzan M.
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
    Richard DJ, Verheijen JC, Zask A.
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.